亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

"MRD Detection Assay," New Markers for Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia (SJ-11-0025)

詳細技術說明
Researchers at St. Jude have identified a set of twenty two markers that predicts minimal residual disease in B-lineage acute lymphoblastic leukemia (ALL) patients. MRD detection by flow cytometry wi
*Abstract
Researchers at St. Jude have identified a set of twenty two markers that predicts minimal residual disease in B-lineage acute lymphoblastic leukemia (ALL) patients. MRD detection by flow cytometry with these antibodies correlated well with those of molecular testing, which is more expensive and requires technical expertise. When used in 6-marker combinations, the new markers can detect one leukemic cell among 105 bone marrow cells, as compared to standard 4-color cytometry that detects one leukemic cell in 104 normal cells. Granted patents or published applications: International application published on Oct 4, 2012 as WO 2012/134813Related scientific references: Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D; New markers for minimal residual disease detection in acute lymphoblastic leukemia; Blood. 2011 Apr 12.
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備